ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Siam Bioscience to produce Oxford COVID-19 vaccine for ASEAN

Thai company receives tech transfer from AstraZeneca for launch by mid-2021

Siam Bioscience will set up production facilities for a potential COVID-19 vaccine developed by the University of Oxford.   © Reuters

BANGKOK -- Thai biopharmaceutical company Siam Bioscience has signed an agreement to partner with U.K.-based drug major AstraZeneca to produce and supply potential COVID-19 vaccine AZD1222, developed by the University of Oxford, for Thailand and Southeast Asian countries.

Thai Deputy Prime Minister and Public Health Minister Anutin Charnvirakul, said on Monday that all parties agreed to prepare large-scale manufacturing capacity at Siam Bioscience. AstraZeneca will be providing the potential vaccine at no profit during the pandemic, while Siam Bioscience is to set up the manufacturing facilities through technology transfer from the European giant.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more